organization · Reporting owner

GREAT POINT PARTNERS LLC

Disclosed activity across 2 companies

Tapewire entity: 118039
SEC CIK: 0001281446

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Adamas Pharmaceuticals Inc

Report date June 19, 2017 · Filed June 22, 2017

Jointly reported with JAY JEFFREY R, KROIN DAVID

Section 16 reporting ended · disclosed 2017-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectInvestment Mgr.	2,251,351	Reported balance After 2017-06-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-06-19 · Sale · Disposed 350,000 · Balance 2,251,351 F1: Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F2: Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
Common StockSEC Table I · non-derivative	IndirectInvestment Mgr.	2,231,351	Reported balance After 2017-06-20 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-06-20 · Sale · Disposed 20,000 · Balance 2,231,351 F4: Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F5: Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
Common StockSEC Table I · non-derivative	IndirectInvestment Mgr.	2,216,351	Reported balance After 2017-06-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2017-06-21 · Sale · Disposed 10,000 · Balance 2,216,351 F6: Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F7: Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F2: Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F3: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

F4: Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F5: Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F6: Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F7: Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

Foamix Pharmaceuticals Ltd.

Report date September 13, 2018 · Filed September 15, 2018

Jointly reported with JAY JEFFREY R, KROIN DAVID

Section 16 reporting ended · disclosed 2018-09-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectInvestment Manager	4,781,708	Reported balance Holding disclosure · report date 2018-09-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,781,708 F1: Consists of 1,400,081 shares owned by Biomedical Value Fund, L.P. ("BVF"), 1,809,973 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 1,395,476 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 176,178 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F2: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of 1,400,081 shares owned by Biomedical Value Fund, L.P. ("BVF"), 1,809,973 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 1,395,476 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 176,178 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

F2: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 21, 2017 Filed Jun 22, 2017 00:48 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	SaleCommon Stock	10,000	$17.44	$174,365.00	Disclosure SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 3 GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner JAY JEFFREY R · CIK 0001239607 · 10% owner KROIN DAVID · CIK 0001397513 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Investment Mgr. Disclosed balance after: 2,216,351 F6 · shares: Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F7 · balance_after: Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. Read SEC document
June 20, 2017 Filed Jun 22, 2017 00:48 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	SaleCommon Stock	20,000	$17.35	$346,934.00	Disclosure SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 2 GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner JAY JEFFREY R · CIK 0001239607 · 10% owner KROIN DAVID · CIK 0001397513 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Investment Mgr. Disclosed balance after: 2,231,351 F4 · shares: Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F5 · balance_after: Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. Read SEC document
June 19, 2017 Filed Jun 22, 2017 00:48 UTC	Adamas Pharmaceuticals Inc ADMS · Entity 133085	SaleCommon Stock	350,000	$17.05	$5,967,675.00	Disclosure SEC source: 0000930413-17-002350 · c88691_4.xml · nonDerivative · entry 1 GREAT POINT PARTNERS LLC · CIK 0001281446 · 10% owner JAY JEFFREY R · CIK 0001239607 · 10% owner KROIN DAVID · CIK 0001397513 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Investment Mgr. Disclosed balance after: 2,251,351 F1 · shares: Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F2 · balance_after: Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS"). F3 · ownership.nature: Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.